A phase I, open-label, multi-center, dose ... - Annals of Oncology
https://www.annalsofoncology.org/article/S0923-7534(19)43996-3/fulltext
WEBOct 1, 2016 · A phase I, open-label, multi-center, dose escalation study of oral NVP-CGM097, a p53/HDM2-protein-protein interaction inhibitor, in adult patients with selected advanced solid tumors - Annals of Oncology. Property. Value. Status. Version.
DA: 55 PA: 6 MOZ Rank: 34